Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

BACKGROUND: We examined whether atorvastatin affects diabetic kidney disease and whether the effect of atorvastatin on cardiovascular disease (CVD) varies by kidney status in patients with diabetes. STUDY DESIGN: The Collaborative Atorvastatin Diabetes Study (CARDS) randomized placebo-controlled tr...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Colhoun, H, Betteridge, D, Durrington, P, Hitman, G, Neil, H, Livingstone, S, Charlton-Menys, V, DeMicco, D, Fuller, J
Format:	Journal article
Sprache:	English
Veröffentlicht:	2009

Ähnliche Einträge

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
von: Charlton-Menys, V, et al.
Veröffentlicht: (2009)

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
von: Colhoun, H, et al.
Veröffentlicht: (2005)

Safety of atorvastatin in the collaborative AtoRvastatin diabetes study (CARDS)
von: Newman, C, et al.
Veröffentlicht: (2006)

Effect of atorvastatin in patients 65 years of age with type 2 diabetes: Subgroup analysis from the collaborative atorvastatin diabetes study (CARDS)
von: DeMicco, D, et al.
Veröffentlicht: (2005)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
von: Raikou, M, et al.
Veröffentlicht: (2007)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
von: Colhoun, H, et al.
Veröffentlicht: (2004)

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)
von: Charlton-Menys, V, et al.
Veröffentlicht: (2009)

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
von: Newman, C, et al.
Veröffentlicht: (2008)

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
von: Hitman, G, et al.
Veröffentlicht: (2007)

Effect of atorvastatin on stroke in the collaborative atorvastatin diabetes study (CARDS): Factors predictive of the risk of stroke
von: Newman, C, et al.
Veröffentlicht: (2005)

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
von: Neil, H, et al.
Veröffentlicht: (2006)

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
von: Charlton-Menys, V, et al.
Veröffentlicht: (2009)

Change in Lp-PLA2 With Risk Change on Statin Therapy in the Collaborative Atorvastatin Diabetes Study (CARDS)
von: Betteridge, D, et al.
Veröffentlicht: (2009)

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
von: Thomason, M, et al.
Veröffentlicht: (2004)

Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)
von: Hitman, G, et al.
Veröffentlicht: (2005)

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
von: Colhoun, H, et al.
Veröffentlicht: (2002)

Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation
von: Raikou, M, et al.
Veröffentlicht: (2005)

C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in CARDS
von: Charlton-Menys, V, et al.
Veröffentlicht: (2009)

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease
von: Soedamah-Muthu, S, et al.
Veröffentlicht: (2011)

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
von: Colhoun, H, et al.
Veröffentlicht: (2011)

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
von: Soedamah-Muthu, S, et al.
Veröffentlicht: (2003)

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
von: Harshal A. Deshmukh, et al.
Veröffentlicht: (2012-05-01)

Relationship between atorvastatin dose and the harm caused by torcetrapib
von: Philip J. Barter, et al.
Veröffentlicht: (2012-11-01)

Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials
von: Liffert Vogt, et al.
Veröffentlicht: (2019-05-01)

Atorvastatin in the secondary prevention of cardiovascular diseases
von: N. A. Vaulin
Veröffentlicht: (2014-12-01)

Statines in treatment of patients with diabetes mellitus: niche of atorvastatine
von: S. A. Urazgildeeva
Veröffentlicht: (2018-03-01)

FREQUENCY AND CORRELATES OF MYOPATHY IN PATIENTS WITH DIABETES TAKING ATORVASTATIN
von: Kamil Rehman Butt, et al.
Veröffentlicht: (2021-04-01)

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin
von: Kwok Leung Ong, et al.
Veröffentlicht: (2018-01-01)

Effect of combined Atorvastatin and zinc oxide on the biochemical and histopathological alterations in kidney of diabetic rats
von: Zahra Karampour Gebchag, et al.
Veröffentlicht: (2019-06-01)

Atorvastatin ascorbic acid cocrystal strategy to improve the safety and efficacy of atorvastatin
von: Sunil Kumar Karumuri Taraka, et al.
Veröffentlicht: (2022-04-01)

Monacolin and atorvastatin in cardiovascular prevention – an attempt at positioning
von: Marcin Barylski
Veröffentlicht: (2017-03-01)

The Effect of Atorvastatin on Inslin Resistance in Patients with Type Two Diabetes
von: Afsaneh Talaei, et al.
Veröffentlicht: (2019-06-01)

The Effect of Atorvastatin on Inflammatory Markers in Patients with Type Two Diabetes
von: Afsaneh Talaei, et al.
Veröffentlicht: (2018-08-01)

Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy.
von: Aude Carillion, et al.
Veröffentlicht: (2017-01-01)

Evaluation of the effects of atorvastatin on renal ischemia-reperfusion in diabetic rats
von: Leila Pirmoradi, et al.
Veröffentlicht: (2020-11-01)

Atorvastatin and cardiovascular risk in the elderly – patient considerations
von: Subroto Acharjee, et al.
Veröffentlicht: (2008-06-01)

The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes
von: Colin Davenport, et al.
Veröffentlicht: (2015-01-01)

Comparison of the Neuroprotective Effects of Aspirin, Atorvastatin, Captopril and Metformin in Diabetes Mellitus
von: Maryam Paseban, et al.
Veröffentlicht: (2019-03-01)

Therapeutic Response of Serum Lipids to Atorvastatin in Type II Diabetic Patients
von: Riyadh M. Murtadha
Veröffentlicht: (2017-03-01)

Therapeutic Response of Serum Lipids to Atorvastatin in Type II Diabetic Patients
von: Riyadh M. Murtadha
Veröffentlicht: (2017-02-01)